Unlock Exclusive Discounts & Flash Sales! Click Here to Join the Deals on Every Wednesday!
Multiple biomarkers are being evaluated to guide the use of immune checkpoint inhibitors in non-small cell lung cancer (NSCLC), including staining of programmed death-ligand 1 (PD-L1) tumor cells. We can accurately quantify PD-L1 status and identify multiple mutations by using a single bronchoscopic specimen.